News & Updates

Join As Board

Dear Reviewer, You can join our Reviewer team without given any charges in our journal. Submit Details on below link: Join As Board

Submit Article

Dear Authors, Article publish in our journal for Volume-1,Issue-1. For article submission on below link: Submit Manuscript

EVALUATION OF THE ANTIPYRETIC POTENTIAL OF CYPERUS SCARIOSUS EXTRACT

Area: Department of Pharmacology
Abstract: Fever (pyrexia) is one of the most prevalent clinical symptoms encountered in primary healthcare worldwide, and the search for safer, plant-derived antipyretic agents has intensified in recent decades. Cyperus scariosus R.Br. (family Cyperaceae), commonly known as Nagarmotha or Cypriol, is a perennial aromatic sedge whose rhizomes have been used for centuries in Ayurveda, Siddha, Unani and folk medicine across the Indian subcontinent for the management of fever, inflammation, digestive disorders and skin ailments. Despite a substantial body of primary research, no comprehensive synthesis of its antipyretic evidence has been published. The present review undertakes a structured meta-analysis of past work on the antipyretic activity of C. scariosus, drawing on twenty-eight original investigations published between 2005 and 2024, together with supporting ethnopharmacological and phytochemical literature. Studies were retrieved from PubMed, Scopus, Web of Science, ScienceDirect and Google Scholar using predefined search terms and were screened against explicit inclusion criteria. Quantitative synthesis of yeast-induced pyrexia models in rodents indicates that methanolic and aqueous rhizome extracts at doses of 200-400 mg/kg produce a 42-82 percent inhibition of fever, approaching the efficacy of paracetamol at higher doses. Phytochemical and docking studies implicate sesquiterpenes such as cyperene, cyperotundone and mustakone, together with flavonoids and phenolics, in the modulation of prostaglandin E2 synthesis via cyclooxygenase-2 inhibition. Critical appraisal reveals methodological heterogeneity, small sample sizes, limited dose standardisation and an absence of clinical trials. The review consolidates current evidence, identifies research gaps, and proposes a roadmap for rigorous preclinical and clinical validation of C. scariosus as a complementary antipyretic agent.
Author: Vishal Malviya¹, Dr. Kailash Kumar Pathak², Firoz Khan3
DOI: MJAP/05/3053
Page: 47-63
Paper Id: 3053
Publication Date: 17-Nov-2026
Download:
© 2024 MJAP. All rights reserved. Developed By Inclusion Web